Thesis (Ph. D.)--University of Texas at Austin, 2007. / Vita. Includes bibliographical references.

A general and efficient methodology for the synthesis of cis-2-substituted-1,2-dihydro-1-naphthols and 2-substituted-1-naphthols from oxabenzonorbornadienes was developed. The procedure involved the sequential palladium-catalyzed ring opening of oxabenzonorbornadienes with aryl or vinyl halides followed by oxidation of the intermediate dihydronaphthols with IBX. The scope of the palladium-catalyzed coupling was extended to a variety of halides such as aryl iodides and bromides bearing both electron-withdrawing and -donating groups, vinyl bromides, and glycal iodides. Oxidation of cis-2-substituted-1,2-dihydro-1-naphthols using IBX led to 2-substituted-1-naphthols in good to excellent yields. Application of such methodologies successfully led to a Group II C-aryl glycoside model. The double intramolecular benzyne-furan cycloadditions and naphthyne-furan cycloadditions were developed. In the model studies, furans and the reacting benzynes or naphthynes were linked with silicon tethers and, thus, the regiochemistry of Diels-Alder cycloadditions could be controlled. Two different tactics for converting the resultant oxabenzonorbornadienes to substituted anthrarufins were demonstrated. The first method entails the initial cleavage of the silicon tethers followed by regioselective ring opening of the oxabenzonorbornadienes and oxidation of the central ring giving the target anthrarufin, whereas the second features the regioselective ring opening of the oxabenzonorbornadienes followed by protiodesilylation and oxidation. Application of the chemistry demonstrated in the model double benzyne-furan cycloadditions successfully led to a total synthesis of vineomycinone B2 methyl ester. This strategy enables the rapid assembly of the glycosyl-substituted aromatic frameworks of complex C-aryl glycoside antibiotics from simple starting materials. We propose an oxidative Mannich reaction for the synthesis of an indole natural product, actinophyllic acid. The synthesis features the selective oxidation of a C3-alkyl indole followed by intramolecular nucleophilic addition of enol ether to build a bicylcic framework. This approach may provide a convergent access to the skeleton of actinophyllic acid. Currently, we have prepared indole 5.77, and continuing efforts will be focused on the formation of azepino[4,3-b]indole 5.78 and the key oxidative Mannich reaction. / text

Thesis (Ph. D.)--University of Chicago, 1942. / Lithoprinted. Includes bibliographical references.

Thesis (Ph.D.)--University of Iowa, 2009. / Thesis supervisor: Tonya L. Peeples. Includes bibliographical references (leaves 78-85); author's personal publications cited on leaf 101.

The γ-o-substituted-phenylparaconic acids were prepared by a method patterned after that of Fuson. These paraconic acids were prepared in good yield. A re-investigation of the Perkin and Fittig methods of preparing γ-phenylisocrotonic acid was carried out without success. The synthesis of γ-o-halophenylisocrotonic acids by thermal, and catalyzed decarboxylation of γ-o-halophenylparaconic acid, have been carried out in good yield. An effective catalyst, optimum temperature and reaction period of decarboxylation of the γ-o-halophenylparaconic acids have been.determined. Infrared absorptions have characterized the γ-o-halophenylisocrotonic acids formed to be in the stable trans form. Cyclization of γ-o-halophenylisocrotonic acids was accomplished by isomerization of the trans acid to cis acid by ultra-violet irradiation, followed by refluxing in the presence of sodium acetate and acetic anhydride. The subsequent hydrolysis of the acetylatednaphthol afforded the 5-halo-l-naphthol.

Isolated from Spongosorites sp., Dragmacidin E is of synthetic interest due to its biological properties and novel molecular structure. A promising therapeutic target, its synthetic challenge is attributed to its heptacyclic core. In this study, we propose the synthesis of a Dragmacidin E heptacyclic core precursor, mediated through a Lewis acid (LA) mediated cyclization of an acceptoreptor-donor (AAD) cyclopropane. Utilizing a model study, alkoxy AAD cyclopropanes were investigated to develop a protocol for precursor synthesis. After generating various ethyl-α-diazobenzoyl acetate derivatives, the metal catalyzed cyclopropanation reaction of these compounds was studied. With vinyl acetate and Rh2esp2, acetoxy AAD cyclopropanes were synthesized in yields ranging from 12 % - 53 %. These cyclopropanes were successfully generated and rearrangement into dihydrofuran products was avoided. To complete our model study, LA cyclization of acetoxy AAD cyclopropanes was studied. Using stoichiometric quantities of TiCl4<.sub>, naphthol derivatives were synthesized in one step.

Biocatalysis involves the use of enzymes to perform stereo- and enantio-specific reactions. One of the reactions where biocatalysis is a valuable technology is oxidation of naphthalene to 1-naphthol using Toluene ortho-Monooxygenase (TOM) variant TmoA3 V106A, also known as TOM-Green. Whole-cell biocatalysis in a water-organic solvent biphasic system was used to minimize naphthalene and 1-naphthol toxicity, and to increase substrate loading. Recombinant Escherichia coli TG1 cells expressing TOM-Green were used for biphasic biocatalysis and lauryl acetate gave best results among the solvents tested. On a constant volume basis, 8 - fold improvement in 1-naphthol production was achieved using biphasic systems compared to biotransformation in aqueous medium. The organic phase was optimized by studying the effects of organic phase ratio and naphthalene concentration in the organic phase. The efficiency of biocatalysis was further improved by application of a solvent tolerant strain Pseudomonas putida S12. P. putida S12 is solvent tolerant owing to its two adaptive mechanisms: outer membrane modification and solvent extrusion using solvent resistant pump srpABC. P. putida S12, in addition to its tolerance to various organic solvents, showed better tolerance to naphthalene compared to E. coli TG1 strain expressing TOM-Green. Application of solvent tolerant P. putida S12 further improved 1-naphthol productivity by approximately 42%. Solvent tolerance of P. putida S12 was further analyzed by transferring its tolerance to a solvent sensitive E. coli strain by transfer of solvent resistant pump srpABC genes. Engineered E. coli strain bearing srpABC genes either in low-copy number plasmid or high-copy number plasmid grew in the presence of a saturated toluene concentration. Engineered E. coli strains were also more tolerant to toxic solvents, e. g., decanol and hexane, compared to the control E. coli strain without srpABC genes. The expression of solvent resistant pump genes was confirmed by Reverse Transcriptase PCR analysis. The main drawbacks of biocatalysis for production of chemicals were addressed and approaches to minimize the drawbacks have been presented. The production of 1-naphthol was significantly improved using biocatalysis in liquid-liquid biphasic systems.

Diss. (sammanfattning) Stockholm : Karol. inst., 2003. / Härtill 5 uppsatser.

A duloxetina (DLX) é um duplo inibidor seletivo balanceado da recaptação de serotonina e norepinefrina empregado para o tratamento do transtorno depressivo maior e para o manejo da dor neuropática diabética periférica. O objetivo deste estudo foi desenvolver e validar métodos analíticos para determinação de DLX em cápsulas e realizar estudos da estabilidade do fármaco. A substância usada como padrão de referência nas análises foi caracterizada por espectroscopia no infravermelho, ressonância magnética nuclear (RMN), calorimetria diferencial de varredura e espectrometria de massas. As análises qualitativas foram realizadas por cromatografia em camada delgada (CCD), espectrofotometria na região do ultravioleta (UV) e cromatografia líquida de alta eficiência (CLAE) permitindo a identificação do fármaco no produto farmacêutico. A espectrofotometria UV, CLAE e voltametria de redissolução catódica (CSV) foram validadas para determinação quantitativa de DLX em cápsulas. Estes métodos propostos foram específicos, robustos, lineares, precisos e exatos para determinação de DLX em microgrânulos de revestimento entérico. Estudos preliminares da estabilidade da DLX durante o desenvolvimento do método indicativo de estabilidade por CLAE demonstraram que o fármaco foi rapidamente degradado em meio ácido, na presença de peróxido de hidrogênio e de radiação a luz UVC, enquanto que este foi mais estável em meio alcalino. A cinética de degradação descreveu as mudanças na concentração da DLX em condição ácida e sob fotodegradação. A degradação ácida da DLX, em solução de HCl 0,1 M, mostrou cinética aparente de zero ordem e a fotodegradação demonstrou uma cinética aparente de primeira ordem. O produto de degradação principal observado na hidrólise ácida (PDA-14) foi analisado e isolado por CCD preparativa. Espectros de RMN-1H, RMN-13C e COSY foram avaliados e a estrutura do PDA-14 foi confirmada como 1-naftol. Esta substância produz efeitos citotóxicos e consequentemente o produto farmacêutico é uma cápsula de gelatina contendo microgrânulos com revestimento entérico para evitar a degradação ácida da DLX no estômago. / The duloxetine (DLX) is a double balanced selective serotonin and norepinephrinereuptake inhibitor employed for the treatment of major depressive disorder and for the management of diabetic peripheral neuropathic pain. The aim of this study was to develop and validate analytical methods to the determination of DLX in capsules and accomplish studies of this drug stability. The substance used as reference standard in the analysis was characterized by infrared spectroscopy, nuclear magnetic resonance (NMR), differential scanning calorimetry, and mass spectrometry. The qualitative analyses were performed by thin layer chromatography (TLC), ultraviolet spectrophotometry (UV), and high performance liquid chromatography (HPLC) allowing the identification of the drug in pharmaceutical dosage form. The UV spectrophotometry, HPLC, and cathodic stripping voltammetry (CSV) were validated for quantitative determination of the DLX in capsules. These proposed methods were specific, robust, linear, precise, and accurate to the determination of DLX in entericcoated pellets. Preliminary studies of DLX stability during the development of stability-indicating HPLC method demonstrated that the drug was rapidly degraded in acid medium, in the presence of hydrogen peroxide and light UVC radiation, while it was more stable in alkali medium. The kinetics of degradation described the concentration changes of DLX in acid condition and on photodegradation. The acid degradation of DLX in 0.1M HCl solution showed apparent zero-order kinetics and the photodegradation demonstrated apparent first-order kinetics. The main degradation product observed in acid hydrolysis (DP-14) was analyzed and isolated by TLC preparative. 1H NMR, 13C NMR and COSY spectra were evaluated and the structure of DP-14 was confirmed as 1-naphthol. This substance produces cytotoxic effects and consequently the finished pharmaceutical dosage form is a gelatin capsule containing enteric-coated pellets to avoid the acid degradation of DLX in the stomach.

A duloxetina (DLX) é um duplo inibidor seletivo balanceado da recaptação de serotonina e norepinefrina empregado para o tratamento do transtorno depressivo maior e para o manejo da dor neuropática diabética periférica. O objetivo deste estudo foi desenvolver e validar métodos analíticos para determinação de DLX em cápsulas e realizar estudos da estabilidade do fármaco. A substância usada como padrão de referência nas análises foi caracterizada por espectroscopia no infravermelho, ressonância magnética nuclear (RMN), calorimetria diferencial de varredura e espectrometria de massas. As análises qualitativas foram realizadas por cromatografia em camada delgada (CCD), espectrofotometria na região do ultravioleta (UV) e cromatografia líquida de alta eficiência (CLAE) permitindo a identificação do fármaco no produto farmacêutico. A espectrofotometria UV, CLAE e voltametria de redissolução catódica (CSV) foram validadas para determinação quantitativa de DLX em cápsulas. Estes métodos propostos foram específicos, robustos, lineares, precisos e exatos para determinação de DLX em microgrânulos de revestimento entérico. Estudos preliminares da estabilidade da DLX durante o desenvolvimento do método indicativo de estabilidade por CLAE demonstraram que o fármaco foi rapidamente degradado em meio ácido, na presença de peróxido de hidrogênio e de radiação a luz UVC, enquanto que este foi mais estável em meio alcalino. A cinética de degradação descreveu as mudanças na concentração da DLX em condição ácida e sob fotodegradação. A degradação ácida da DLX, em solução de HCl 0,1 M, mostrou cinética aparente de zero ordem e a fotodegradação demonstrou uma cinética aparente de primeira ordem. O produto de degradação principal observado na hidrólise ácida (PDA-14) foi analisado e isolado por CCD preparativa. Espectros de RMN-1H, RMN-13C e COSY foram avaliados e a estrutura do PDA-14 foi confirmada como 1-naftol. Esta substância produz efeitos citotóxicos e consequentemente o produto farmacêutico é uma cápsula de gelatina contendo microgrânulos com revestimento entérico para evitar a degradação ácida da DLX no estômago. / The duloxetine (DLX) is a double balanced selective serotonin and norepinephrinereuptake inhibitor employed for the treatment of major depressive disorder and for the management of diabetic peripheral neuropathic pain. The aim of this study was to develop and validate analytical methods to the determination of DLX in capsules and accomplish studies of this drug stability. The substance used as reference standard in the analysis was characterized by infrared spectroscopy, nuclear magnetic resonance (NMR), differential scanning calorimetry, and mass spectrometry. The qualitative analyses were performed by thin layer chromatography (TLC), ultraviolet spectrophotometry (UV), and high performance liquid chromatography (HPLC) allowing the identification of the drug in pharmaceutical dosage form. The UV spectrophotometry, HPLC, and cathodic stripping voltammetry (CSV) were validated for quantitative determination of the DLX in capsules. These proposed methods were specific, robust, linear, precise, and accurate to the determination of DLX in entericcoated pellets. Preliminary studies of DLX stability during the development of stability-indicating HPLC method demonstrated that the drug was rapidly degraded in acid medium, in the presence of hydrogen peroxide and light UVC radiation, while it was more stable in alkali medium. The kinetics of degradation described the concentration changes of DLX in acid condition and on photodegradation. The acid degradation of DLX in 0.1M HCl solution showed apparent zero-order kinetics and the photodegradation demonstrated apparent first-order kinetics. The main degradation product observed in acid hydrolysis (DP-14) was analyzed and isolated by TLC preparative. 1H NMR, 13C NMR and COSY spectra were evaluated and the structure of DP-14 was confirmed as 1-naphthol. This substance produces cytotoxic effects and consequently the finished pharmaceutical dosage form is a gelatin capsule containing enteric-coated pellets to avoid the acid degradation of DLX in the stomach.